The BRCP/ABCG2 expression level at initial diagnosis in the Refractory DLBCL was significantly higher (54.59% ± 8.27) than either Relapsed (44.81% ± 5.06) or Remission DLBSL (29.03% ± 8.6), p < 0.001, respectively (Figure 2). The gene discussed is ABCG2; the disease is diffuse large B-cell lymphoma.